RenovoRx prices $12.1M underwritten public offering of 11.5M shares at $1.05 per share

RenovoRx, Inc.

Offering of 11,523,810 shares at $1.05/share; gross proceeds ~$12.1M, net ~$10.9M after underwriting discounts and expenses.
Closing expected February 10, 2025; underwriter warrants issued for 576,191 shares at $1.21/share.
Proceeds to fund Phase III TIGeR-PaC study and commercial activities for RenovoCath device.
Titan Partners Group acted as sole bookrunner for the firm commitment offering.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.